Patent · US Active

Modulators of C3a receptors

US9586914B2 · kind B2 · utility

4Cited by

0References

26Claims

0Family size

Assignee

The University Of Queensland · AU

Inventors

David Fairlie · Faulconbridge, AU
Robert C. Reid · Calle de la Era, AU

Key dates

Filing date	Nov 7, 2012
Grant date	Mar 7, 2017
Priority date	—
Expiry date	Nov 12, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/55511
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Heterocyclic compounds that modulate C3a receptors and their use in the treatment or prevention of inflammatory diseases, infectious diseases, cancers, metabolic disorders, obesity, type 2 diabetes, metabolic syndrome and associated cardiovascular diseases are described. The use of the compounds in stimulating or suppressing an immune response is also described together with pharmaceutical compositions comprising the compounds or their pharmaceutically acceptable salts.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.